Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2016 - 2026)

Pharma-Bio Serv's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $13.5 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity fell 15.73% year-over-year to $13.5 million; the TTM value through Jan 2026 reached $54.7 million, down 16.65%, while the annual FY2025 figure was $13.7 million, 16.2% down from the prior year.
  • Liabilities and Shareholders Equity reached $13.5 million in Q1 2026 per PBSV's latest filing, down from $13.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.9 million in Q1 2023 to a low of $13.5 million in Q1 2026.
  • Average Liabilities and Shareholders Equity over 5 years is $18.0 million, with a median of $19.2 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 28.91% in 2022, then increased 3.74% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $20.7 million in 2022, then decreased by 3.63% to $19.9 million in 2023, then dropped by 18.14% to $16.3 million in 2024, then fell by 16.2% to $13.7 million in 2025, then decreased by 0.77% to $13.5 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Liabilities and Shareholders Equity are $13.5 million (Q1 2026), $13.7 million (Q4 2025), and $13.6 million (Q3 2025).